Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


First published on August 1, 2008
This version was published on August 8, 2008
Neuro Oncol 2008, DOI:10.1215/15228517-2008-0047
This Article
Right arrow Advance Publication Full Text (PDF)
Right arrow All Versions of this Article:
15228517-2008-0047v2    most recent
15228517-2008-0047v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, M. C.
Right arrow Articles by Marcinkiewicz, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Copyright 2008 by the Society for Neuro-Oncology

Received February 14, 2008
Accepted April 28, 2008

Basic and Translational Investigations

Regulatory effect of nerve growth factor in {alpha}9{beta}1 integrin-dependent progression of glioblastoma

Meghan C. Brown 1, Izabela Staniszewska 1, Philip Lazarovici 2, George P. Tuszynski 1, Luis Del Valle 1, Cezary Marcinkiewicz 1*

1 Department of Neuroscience, Center for Neurovirology and Cancer Biology, Temple University, School of Medicine, Philadelphia, PA 19122, USA
2 The Hebrew University of Jerusalem, School of Pharmacy, Jerusalem 91120, Israel

* To whom correspondence should be addressed. E-mail: cmarcink{at}temple.edu.


   Abstract

In the presented study we described the role of {alpha}9{beta}1 integrin in glioblastoma progression following its interaction with NGF. The level of expression of {alpha}9{beta}1 on astrocytomas is correlated with increased grade of this brain tumor, and is the highest on glioblastoma, whereas normal astrocytes do not express this integrin. Two glioblastoma cell lines, LN229 and LN18 that are {alpha}9{beta}1 integrin positive or negative, respectively, were used for {alpha}9{beta}1 integrin-dependent NGF-induced tumor progression. NGF was a significant promoter of pro-migratory and proproliferative activities of glioblastoma cells through direct interaction with {alpha}9{beta}1 integrin and activation of MAPK Erk1/2 pathway. The level of NGF increases approximately 3 fold in the most malignant glioma tissue if compared with normal brain. This increase is related to secretion of NGF by tumoral cells. Specific inhibitors of {alpha}9{beta}1 integrin or gene silencing inhibited NGF- induced proliferation of LN229 cell line to the level showed by LN18 cells. VLO5 promoted {alpha}9{beta}1-dependent programmed cell death by induction of intrinsic apoptosis pathway in cancer cells. LN229 cells were rescued from pro-apoptotic effect of VLO5 by the presence of NGF. This disintegrin significantly inhibited tumor growth induced by implantation of LN229 cells to the CAM of quail embryonic model and this inhibitory effect was significantly abolished by the presence of NGF. {alpha}9{beta}1 integrin appears to be an interesting target for blocking of progression malignant gliomas, especially in light of the stimulatory effect of NGF on development of this tumor and ability to transfer pro-apoptotic signal in cancer cells.

Key Words: apoptosis, disintegrins, glioblastoma, integrins, NGF


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


Copyright 2008 by Society for Neuro-Oncology